姜黄素抑制内镜切除后复发性结直肠腺瘤生长:随机双盲安慰剂对照多中心试验
这项随机双盲安慰剂对照多中心试验纳入577例既往内镜切除结直肠肿瘤患者,随机接受口服姜黄素180mg每日两次或安慰剂2年。2年复发性结直肠腺瘤检出率两组无显著差异(RR 0.98,95%CI 0.82-1.16),但姜黄素组≥6mm腺瘤检出率显著降低(RR 0.56,95%CI 0.33-0.95,P=0.04)。
要点
- 姜黄素未降低2年复发性结直肠腺瘤总体检出率
- 姜黄素显著降低≥6mm腺瘤检出率及人均数量
- 姜黄素组所有检出腺瘤中位大小显著更小
核心结论
- 姜黄素抑制复发性结直肠腺瘤生长,但未显著降低总体复发率。
研究设计与样本
- 随机双盲安慰剂对照多中心试验,纳入577例既往内镜切除结直肠肿瘤患者,按1:1随机接受口服姜黄素180mg每日两次或安慰剂2年。
主要发现
- 2年复发性结直肠腺瘤检出率两组无显著差异(RR 0.98,95%CI 0.82-1.16)。
- ≥6mm腺瘤检出率姜黄素组显著降低(RR 0.56,95%CI 0.33-0.95,P=0.04)。
- ≥6mm腺瘤人均数量显著降低(P=0.03),所有检出腺瘤中位大小显著更小(P=0.003)。
- 探索性分析中抑制效应在基线腺瘤负荷较高者和男性中似更明显。
- 治疗相关不良事件少见且轻微。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Experimental and limited clinical studies suggest that curcumin has chemopreventive activity in the colorectum. This large-scale clinical trial evaluated the efficacy and safety of curcumin in patients with previously endoscopically resected colorectal neoplasia. METHODS: This randomized, double-blind, placebo-controlled multicenter trial enrolled patients with previously resected colorectal neoplasia. Eligible patients were randomly assigned (1:1), using a stratified, computer-generated scheme to receive oral submicron-powdered curcumin (Theracurmin; 180 mg twice daily) or identical placebo capsules for 2 years. All analyses were performed according to a modified intention-to-treat principle including all randomly assigned patients who underwent the 2-year colonoscopy. RESULTS: Between April 1, 2016, and March 31, 2020, 577 patients were randomly assigned to curcumin (n = 287) or placebo groups (n = 290). The detection rate of recurrent colorectal adenomas at 2 years, the primary end point, did not differ significantly between groups (risk ratio 0.98; 95% confident interval 0.82-1.16). However, the detection rate of adenomas ≥6 mm, a prespecified lesion category recommended for endoscopic resection in Japanese guidelines, was significantly lower with curcumin (risk ratio, 0.56; 95% confident interval, 0.33-0.95; P = 0.04). The per-patient number of adenomas ≥6 mm was also significantly lower ( P = 0.03), and the median size of all detected adenomas was significantly smaller in the curcumin group ( P = 0.003). The inhibitory effect seemed more pronounced in patients with higher baseline adenoma burden and in men in exploratory analyses. Treatment-related adverse events were infrequent and mild. DISCUSSION: Curcumin inhibited the growth of recurrent colorectal adenomas, despite no significant reduction in the overall incidence of recurrence. This is the first large-scale randomized clinical trial demonstrating the suppressive efficacy of curcumin against colorectal neoplasia, and also highlighting the importance of incorporating growth-related endpoints, in addition to incidence-based or detection-based end points, in chemoprevention studies (jRCTs061180079).
引用
- Takayama T, Okamoto K, Ishikawa H, et al. Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Am J Gastroenterol. 2026. PMID: 42669465. doi:10.14309/ajg.0000000000004193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。